ArticleFrontiers in molecular biosciences2025
Comprehensive lipoprotein and glycoprotein characterization in rheumatoid arthritis plasma and association with clinical markers.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and pain. This study investigates plasma lipoprotein and glycoprotein profiles in RA patients to identify clinically relevant markers for disease monitoring. Methods: Lipoprotein composition and subfractions were analyzed in plasma from 161 RA patients and 46 controls using proton nuclear magnetic resonance ( Results: RA patients exhibited a distinct lipoprotein and glycoprotein profile, with increased triglycerides, cholesterol, apolipoproteins (A1, A2, B100), and changes in LDL, HDL, GlycA, and GlycB. Glycoproteins were significantly higher in DMARD-naive RA (AUC ≈ 0.9) validating these NMR signals as biomarkers of inflammation. Patients in remission had higher small dense HDL and lower LDL-triglycerides than those with high disease activity. VAS correlated with LDL-triglycerides, while DAS28 correlated with small dense LDL-triglycerides and glycoproteins, inversely with large LDL, small HDL lipids. H4A1 alone characterizes RA remission (AUC ≈ 0.8). Conclusion: Lipoprotein profiles in RA correlate with disease activity, inflammation, and pain. Large HDL, intermediate LDL and glycoproteins serve for RA monitoring as well as potential molecular markers of pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.